This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
The Truth About Market Timing - March 06, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Simple Secrets Anyone Can Use to Reach Early Retirement - March 06, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
AbbVie (ABBV) Stock Moves -1.21%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $90.64, moving -1.21% from the previous trading session.
Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus
by Zacks Equity Research
Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.
Inovio Surges on Expedited Timeline for Coronavirus Vaccine
by Zacks Equity Research
Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.
Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA
by Zacks Equity Research
Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.
Why You Shouldn't Bet Against AbbVie (ABBV) Stock
by Zacks Equity Research
AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AbbVie's Venclexta Combo Fails in Late-Stage Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with chemotherapy fails to achieve statistically significant improvement in overall survival in treatment-naive AML patients.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $85.62, moving +0.23% from the previous trading session.
How Trading Your Own Retirement Can Fleece Your Financial Future - February 28, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Easy Investing Secrets to an Early Retirement - February 27, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
by Zacks Equity Research
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
One of Your Stock Investments is Being Acquired: Now What?
by Tracey Ryniec
One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.
Signs That Your Trading Will Ruin Your Retirement - February 20, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Easy Investing Secrets to an Early Retirement - February 19, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally
by Zacks Equity Research
ImmunoGen (IMGN) reports fourth-quarter results with earnings and revenues beating estimates.
The Keys to Successfully Timing the Markets - February 14, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
The Zacks Analyst Blog Highlights: AbbVie, Accenture, TOTAL, Amazon.com and Intuit
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Accenture, TOTAL, Amazon.com and Intuit
How Trading Your Own Retirement Can Fleece Your Financial Future - February 11, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Top Stock Research Reports for AbbVie, Accenture, TOTAL & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Accenture (ACN) and TOTAL (TOT).
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Easy Investing Secrets to an Early Retirement - February 10, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AbbVie's (ABBV) Q4 Earnings Beat, 2020 View Solid, Stock Up
by Zacks Equity Research
AbbVie (ABBV) beat on earnings in the fourth quarter of 2019 while revenues meet the same. Shares up in pre-market trading following a solid 2020 outlook.
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
by Kinjel Shah
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.